Stem cell transplant for high-risk CBF-AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a stem cell transplant (using donor cells) for people with a high-risk form of acute myeloid leukemia called CBF-AML. The goal is to see if this transplant can help patients who have a higher chance of the leukemia coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of AML called CBF-AML, found through genetic tests.
- Your leukemia is high-risk, meaning it has certain gene mutations or doesn't fully clear after two chemo treatments.
- You are between 18 and 65 years old.
- Your heart, liver, and kidneys are working well enough to handle the treatment.
- You are not pregnant or breastfeeding, and you agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a stem cell transplant from a donor can help people with a specific type of acute myeloid leukemia (AML) that has a high risk of coming back. It is for patients who have the CEBPA gene mutation and other high-risk features.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This trial tests a stem cell transplant using a half-matched donor, followed by extra immune cells and targeted drugs, for people with acute myeloid leukemia (AML) that is still active or has come back. The goal is to try to control the leukemia and improve outcomes.
This trial tests a new way to do cord blood transplants for people with high-risk leukemia. It adds extra white blood cells (granulocytes) to boost the immune system and help fight the disease, with the goal of improving outcomes.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.